2
Announcements
Trials
Browse
Landscape
Status
Completed
5
No longer available
4
Approved for marketing
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Expanded_access
2
Sponsor
Conditions
Myasthenic Syndromes, Congenital
2
Lambert-Eaton Myasthenic Syndrome
2
Nystagmus, Pathologic
1
Interventions
Afatinib
3
3-Iodobenzylguanidine
3
niraparib
2
lenvatinib
2
ibrutinib
2
gallium 68 PSMA-11
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Ramucirumab
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Gefitinib
2
Fluorouracil
2
Capecitabine
2
Amifampridine
2
Abiraterone Acetate
2
zenocutuzumab
1
vorasidenib
1
tucatinib
1
trilaciclib
1
trifluridine tipiracil drug combination
1
tovorafenib
1
talquetamab
1
tafasitamab
1
selpercatinib
1
sacituzumab govitecan
1
ripretinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Approved for marketing
×
Amifampridine
×
Clear all
NCT02189720
2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
NCT00872950
2022-04-11
LEMS
Lahey Clinic
Approved for marketing